^
    Back
    Association details:
    Biomarker:FGFR1 amplification
    Cancer:Breast Cancer
    Drug:Lytgobi (futibatinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of TAS-120 in Patients With Metastatic Breast Cancer

    Excerpt:
    ...- HR+ HER2- breast cancer harboring an FGFR1 high-level gene amplification...
    Trial ID:
    FOENIX-MBC2 TAS-120-201
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A study to evaluate the effects of TAS-120 in patients with Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications

    Excerpt:
    ...HR+ HER2- breast cancer (defined as above) harboring an FGFR1 high-level gene amplification as defined in Section 6.1.1.1ii. ...
    Trial ID:
    2019-001164-30
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2020
    Title:

    Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

    Published date:
    11/01/2020
    Excerpt:
    Across all tumor types studied, futibatinib inhibited the growth of cell lines with various FGFR genomic aberrations, but not of cell lines that did not harbor such aberrations....These FGFR aberrations included FGFR1/2 amplifications (breast cancer), FGFR1 amplifications (lung cancer), FGFR2 amplifications (gastric cancer), FGFR2 point mutations (endometrial cancer), FGFR3 fusions (bladder cancer), and FGFR3 translocations (multiple myeloma; Table 1...).
    DOI:
    10.1158/0008-5472.CAN-19-2568